Major milestones for CSL Behring’s Hizentra app

We are excited to announce major milestones for CSL Behring’s Hizentra app, which supports patients taking Hizentra with medication reminders, record management, infusion tracking and more. The latest version of the app introduces exciting new capabilities and an updated design. The update also expands the app's footprint geographically, reaching new markets in Latin America and Canada, in addition to the existing regions of the U.S. and Japan.

Hizentra app update

The latest version of the Hizentra app brings additional functionality, including:

• Nurse educator program access for US users
• A new resources page to access CSL Behring’s Knowledge Base content, such as webinars, instructional videos, infusion guides and more
• More flexible patient flows for recording infusions
• A notes feature to privately record and review details of specific infusions (not available in Japan)
• Infusion statistics

Global expansion

The Hizentra app is now available in the U.S., Japan, Canada, Chile and Argentina. Because the app is built on the BrightInsight® Platform, our team was able to localize the app features, graphics and language quickly for these new regions, while meeting security, privacy and regulatory compliance across geographies.

This latest expansion of the Hizentra app demonstrates BrightInsight’s ability to efficiently help our biopharma partners launch and scale their drug companion apps geographically in an agile and compliant manner.

Hizentra app engagement

This global app expansion was driven by significant adoption and high retention rates among users of the U.S. Hizentra app. Specifically:

• The app has earned an adoption rate of over 25% of the brand’s U.S. patient population
• Between June 2021 to June 2022, for patients who started using the app within the 1^st month, we saw 79% retention on the app at 3 months and 71% retention at 12 months, compared to an industry average of 45%¹
• Time to first activity: Of the patients who become users of the app, 76% of them have recorded their first infusion within the first 7 days

This app is also a terrific proof point of how companion apps can capture valuable real-world data for biopharma companies. For example, 250k infusions have been recorded in the Hizentra app to date.

For more information on CSL Behring’s Hizentra app, read our case study.

Source 1: Attentive “2022 Mobile Customer Engagement Benchmark Report”